Trip to Sustainability? This Company Is Developing Synthetic Psychedelics To Attempt to Fight Mental Illness

Photo by Raimond Klavins on Unsplash

The following post was written and/or published as a collaboration between ’s in-house sponsored content team and a financial partner of Benzinga.

Researchers have long experimented with hallucinogenic drugs for the treatment of mental illness.

While many people may be familiar with psychedelic drug advocate Timothy Leary’s experiments with LSD or the known effects of magic mushrooms, what they may not know is that there are a variety of hallucinogens that scientists are studying today in the hopes they will be able to treat addiction and mental illness.

Reportedly among the most promising drugs being studied today is ibogaine, a naturally occurring psychedelic substance derived from the bark and roots of the West African shrub Tabernanthe iboga.

Ibogaine has the potential to treat mental health issues like addiction, depression, and anxiety, but a lack of resources is preventing the and clinical trials from bringing ibogaine treatment to the United States and Canada.

The legal status of ibogaine varies around the globe. It’s illegal in ten …

Full story available on Benzinga.com

More Trip to Sustainability? This Company Is Developing Synthetic Psychedelics To Attempt to Fight Mental Illness